Drugs / UCART019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03166878 | Jun 2017 → May 2022 | lymphoid leukemia, lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCART019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03166878 ↗ |
| Action | Deplete | “help the body's immune system eliminate malignant B-cells” NCT03166878 ↗ |
| Modality | Cell therapy | “allogeneic CD19-directed BBζ CAR-T cells” NCT03166878 ↗ |
| Route | Intravenous | “administered by i.v. injection” NCT03166878 ↗ |
| Target | CD19 | “CD19-directed BBζ CAR-T cells” NCT03166878 ↗ |